Please enable JavaScript.
Coggle requires JavaScript to display documents.
晚期肝癌－免疫合併治療的最新進展 - Coggle Diagram
晚期肝癌－免疫合併治療的最新進展
-
-
-
-
-
-
-
參考資料
十三~十四年
Cheng AL, Kang YK, Chen Z, et al. Efficacy and
safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:
a phase III randomised, double-blind, placebocontrolled trial. The Lancet Oncology 2009;10:25-
34.
Siegel AB, Cohen EI, Ocean A, et al. Phase II
trial evaluating the clinical and biologic effectsof bevacizumab in unresectable hepatocellular
carcinoma. J Clin Oncol 2008;26:2992-8.
五年內
Kudo M, Finn RS, Qin S, et al. Lenvatinibversus sorafenib in first-line treatment of patientswith unresectable hepatocellular carcinoma: arandomised phase 3 non-inferiority trial. Lancet(London, England) 2018;391:1163-73
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumabin patients with advanced hepatocellular carcinoma
(CheckMate 040)): an open-label, non-comparative,
phase 1/2 dose escalation and expansion trial. Lancet (London, England) 2017;389:2492-502
Zhu AX, Finn RS, Cattan S. KEYNOTE224: Pembrolizumab in patients with advancehepatocellular carcinoma previously treated with sorafenib. J Clin Oncol 2018;36:abstr 209.
Cheng AL. Imbrave150: Efficacy and safety results
from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first
treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol
2019;30:ix183-202.
Bang YJ, Golan T, Lin CC, et al. Ramucirumab(Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC),gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma
(HCC) following progression on systemic treatment(s). J Clin Oncoly 2019;37:2528.
Ikeda M, Sung MW, Kudo M, et al. A phase 1b
trial of lenvatinib (LEN) plus pembrolizumab(PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol2018;36:4076.
Robin Kate Kelley GKA-A, Johanna C. Bendell,
Tae-You Kim, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable
hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol 2017;35:4073.
Thomas Y, Kang YK, Kim TY, et al. Nivolumab
(NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular
carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol 2019;37:4012
-